Member Info for EmeraldCarrots

Up 16.67%.

Must be the Bioview news yesterday...................... I presume.

LOL!.

I see you have met.

Up 14.81%

Up 12.96.

Bid?

Nah.......... Hmm............ Astrazeneca maybe?????????????????

Up again - 11.11%!!

Up 9.26%

Up 7.41%.

news yesterday when the sp went up 10%.

Todays it's currently up another 7.4%.

Monitoring the HER2 status of cancers is but one way the Parsortix machine will be a winner.

You only have to read some of the recent Astrazenica RNS's to find out about HER2.

All IMHO.

Up 7.41%.

TwoGood2Die. I bet you are very pleased as you hold some apparently.

Daytraders?

Up 5.5%. Big trades coming in now.

3.7% up now.

so this might be the start of a more prolonged rise.

Which is exactly what Angle Plc are working on with Bioview:-

Astrazeneca RNS of 8th April:-

"Enhertu approved in the US as first tumour-agnostic HER2-directed therapy

for previously treated patients with metastatic HER2-positive solid tumours"

https://www.lse.co.uk/rns/AZN/enhertu-approved-in-us-for-her2-solid-tumours-d992ucbs0xpl3ik.html

Astrazeneca RNS of 2nd April:-

"Datopotamab deruxtecan Biologics License Application accepted in the US for patients with previously treated metastatic HR-positive, HER2-negative breast cancer"

https://www.lse.co.uk/rns/AZN/fda-accepts-dato-dxd-bla-for-breast-cancer-6gb18korpqpp8bb.html

Market...... They need it IMHO.

Blubay

"What is the business scenario in which this would be "5p by end of April"?".

======================

One with similar odds to winning the lottery?

For my shares". LOL!

Posts. It's really quite amusing.

We will see......

Moab

" I see no reason why Parsortix could not be used to help detect the HER-2 levels in all cancer types."

Reason: I think you will find that HER status applies only to breast cancer.".

============================================

Incorrect. The Astrazeneca RNS just yesterday (see link below) names many cancers as you can see:-

"HER2-directed therapies have been used to treat breast, gastric, lung and colorectal cancers for a number of years.3,6,7 Although HER2 is expressed in solid tumour types including biliary tract, bladder, cervical, endometrial, ovarian and pancreatic cancers, testing is not routinely performed in these additional tumour types and as a result, available literature is limited.4 In these solid tumours, HER2-positive expression, classified as immunohistochemistry (IHC) 3+, has been observed at rates from 1% to 28%.8,9 Approximately 1% to 5% of patients with NSCLC have tumours with HER2 overexpression (IHC 3+), however, the levels of protein expression reported vary in the literature.8,10 Approximately 1% to 4% of patients with metastatic colorectal cancer have tumours which are HER2 overexpressing (IHC 3+).8,11,12

https://www.lse.co.uk/rns/AZN/enhertu-approved-in-us-for-her2-solid-tumours-d992ucbs0xpl3ik.html

All IMHO.

New York, February 10, 2022.

Note these are just the trials that include a PD1/PDL1-targeting agent.....................

"The number of clinical trials started each year that include a PD1/PDL1-targeting agent has continued to increase, currently at 5,683 worldwide, up 278% from the number of trials reported in 2017.".

https://www.cancerresearch.org/media-room/2022/pd1-pdl1-clinical-trials-combo-mono

"Breast cancer is the most common cancer worldwide. There were more than 2.26 million new cases of breast cancer in women in 2020."

https://www.wcrf.org/cancer-trends/breast-cancer-statistics/